Posted by Michael Wonder on 29 Oct 2021
Reata Pharmaceuticals submits marketing authorisation application to the EMA for bardoxolone methyl in chronic kidney disease caused by Alport syndrome
28 October 2021 - Reata Pharmaceuticals today announced its submission of a marketing authorisation application for bardoxolone methyl to the EMA for the treatment of patients with chronic kidney disease caused by Alport syndrome.
This submission is based on the efficacy and safety data from the CARDINAL Phase 3 clinical trial.
